Lord, Abbett & Co
AVDL

Lord, Abbett & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

Lord, Abbett & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-489,073
Closed -$6.41M – 527
2024
Q3 		$6.41M Buy
+489,073
New +$7.45M 0.02% 452
2024
Q2 		– Sell
-193,233
Closed -$3.26M – 520
2024
Q1 		$3.26M Buy
+193,233
New +$2.88M 0.01% 506

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Lord, Abbett & Co's AVDL Position: Q4 2024 in Review

Lord, Abbett & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 489,073 shares — an estimated $6.41M sold.

Lord, Abbett & Co first reported a position in AVDL in Q1 2024 and held it in 2 quarters. The position peaked at $6.41M in Q3 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Lord, Abbett & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 489,073 Avadel Pharmaceuticals shares in Q4 2024, an estimated $6.41M.
  • Lord, Abbett & Co first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Lord, Abbett & Co's Avadel Pharmaceuticals position peaked at $6.41M in Q3 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Lord, Abbett & Co's 13F filing for Q4 2024, filed 14 Feb 2025.